European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Decision could significantly improve transplant outcomes for patients with multiple myeloma
BEERSE, Belgium--(Healthcare Sales & Marketing Network)--Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved ... Biopharmaceuticals, Oncology, RegulatoryJanssen, VELCADE, bortezomib, induction therapy, multiple myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Marketing | Myeloma | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Transplants | Velcade